We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.57B
AUM Growth
+$1.06B
Cap. Flow
+$745M
Cap. Flow %
7.79%
Top 10 Hldgs %
36.3%
Holding
159
New
27
Increased
34
Reduced
20
Closed
32

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$202M
2
COO icon
Cooper Companies
COO
+$180M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.3M
4
SHPG
Shire pic
SHPG
+$77.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$75.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$240M
2
VTRS icon
Viatris
VTRS
+$184M
3
AGN
Allergan Inc
AGN
+$107M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$89.3M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0.07%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$167B
$400M 4.18%
3,762,200
+327,400
+10% +$32.1M
BIIB icon
2
Biogen
BIIB
$30.4B
$394M 4.11%
1,190,100
+105,900
+10% +$34.9M
BMY icon
3
Bristol-Myers Squibb
BMY
$130B
$373M 3.9%
7,292,000
+103,000
+1% +$5.14M
AMGN icon
4
Amgen
AMGN
$212B
$366M 3.82%
2,603,000
+358,000
+16% +$46.7M
ICPT
5
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$351M 3.67%
1,485,000
-171,258
-10% -$43.7M
AGN
6
DELISTED
Allergan plc
AGN
$347M 3.62%
1,436,200
+904,200
+170% +$202M
ABBV icon
7
AbbVie
ABBV
$465B
$316M 3.3%
5,478,000
+273,800
+5% +$15.2M
SHPG
8
DELISTED
Shire pic
SHPG
$316M 3.3%
1,219,000
+313,800
+35% +$77.9M
CELG
9
DELISTED
Celgene Corp
CELG
$315M 3.29%
3,328,000
+673,000
+25% +$60.7M
HCA icon
10
HCA Healthcare
HCA
$92.8B
$297M 3.1%
4,213,000
-300,000
-7% -$19.8M
SHPG
11
CALL
DELISTED
Shire pic
SHPG
$246M 2.57%
+950,000
New +$236M
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
$225M 2.35%
4,546,000
-347,200
-7% -$14.8M
ILMN icon
13
Illumina
ILMN
$29.2B
$220M 2.3%
1,380,604
-44,204
-3% -$7.39M
CFN
14
DELISTED
CAREFUSION CORPORATION
CFN
$215M 2.25%
4,756,000
+1,085,000
+30% +$48.9M
TMO icon
15
Thermo Fisher Scientific
TMO
$214B
$206M 2.15%
1,691,400
+155,700
+10% +$18.9M
RLYP
16
DELISTED
RELYPSA INC COM
RLYP
$187M 1.95%
8,857,551
-1,084,000
-11% -$26.3M
ISRG icon
17
Intuitive Surgical
ISRG
$130B
$178M 1.86%
3,477,600
-42,300
-1% -$2.1M
COO icon
18
Cooper Companies
COO
$14.1B
$178M 1.86%
+4,570,800
New +$180M
A icon
19
Agilent Technologies
A
$39.7B
$175M 1.83%
6,010,002
+1,633,843
+37% +$66.7M
PRGO icon
20
Perrigo
PRGO
$1.43B
$172M 1.8%
1,144,700
-37,000
-3% -$5.52M
AGN
21
DELISTED
Allergan Inc
AGN
$160M 1.67%
897,700
-646,000
-42% -$107M
INCY icon
22
Incyte
INCY
$26B
$160M 1.67%
3,254,900
-245,500
-7% -$12.3M
MRK icon
23
Merck
MRK
$326B
$158M 1.65%
2,789,776
+129,952
+5% +$7.3M
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$626M
$156M 1.63%
14,342,447
+3,672,982
+34% +$42M
IPXL
25
DELISTED
Impax Laboratories, Inc.
IPXL
$152M 1.59%
6,405,200
+989,600
+18% +$25.4M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2014 Portfolio in Review

As of Q3 2014, OrbiMed held 159 positions worth $9.57B, up 12% from $8.52B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed deployed $745M of net new capital in Q3 2014, opening 27 new positions and adding to 34 existing holdings. Its largest new stake was Cooper Companies: 4,570,800 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Viatris, an estimated $184M trimmed.

  • OrbiMed's largest Q3 2014 buy was Cooper Companies: 4,570,800 shares worth $178M.
  • OrbiMed added most to Allergan plc in Q3 2014, an estimated $202M increase.
  • OrbiMed's biggest Q3 2014 reduction was Viatris, cutting an estimated $184M.
  • OrbiMed fully exited INTERMUNE INC in Q3 2014, selling an estimated $240M.
  • OrbiMed's ten largest holdings make up 36% of its $9.57B portfolio in Q3 2014.
  • OrbiMed opened 27 new positions and closed 32 in Q3 2014.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $9.57B.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.